PLAUR and cancer: Integrating with the cancer hallmarks analytics tool (CHAT) analysis, a comprehensive global and plasma membrane approach (whole cell lysis with two membrane protein enrichments) using HCT116 cells (derived from Dukes’ stage D CRC) and engineered mutants with reduced uPAR expression followed by IPA analysis demonstrated that uPAR resists most pathways related with HoCs, including sustaining proliferation, evading apoptosis and metastasis [98].